OS6.4 NOA-16: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas

BACKGROUND: In preclinical studies we have defined IDH1R132H as a clonal neoantigen presented on MHC class II. A peptide vaccine encompassing IDH1R132H induces tumor-specific T helper cell responses effective in controlling syngeneic IDH1R132H-mutant tumors in humanized mouse models. MATERIAL AND ME...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Platten, M, Schilling, D, Bunse, L, Wick, A, Bunse, T, Riehl, D, Green, E, Sanghvi, K, Karapanagiotou-Schenkel, I, Harting, I, Sahm, F, Steinbach, J, Weyerbrock, A, Hense, J, Misch, M, Krex, D, Setvanovic, S, Tabatabai, G, von Deimling, A, Schmitt, M, Wick, W
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2018
Materias:
Oral Presentations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144380/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.041
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares